Bafna Pharma Peer Comparison

NSE: BAFNAPH | BSE: 532989

₹418.00

₹8.15 (1.99%)

As on 09-Oct-2026 12:30IST

Market cap

₹989 Cr

Revenue (TTM)

₹143 Cr

P/E Ratio

127

P/B Ratio

10.3

Div. Yield

0 %

Edit

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	989	19,833	19,006	17,198	16,047
Revenue (₹ Cr)	143	1,682	2,287	2,570	3,230
Net Profit (₹ Cr)	7.79	273.51	678.07	735.15	666.92
Net Margin (%)	5.24	16.19	28.10	26.88	20.60
RoE (%)	8.31	11.15	19.73	19.16	18.75
Price to Earnings	126.97	66.71	28.56	23.39	24.92
Price-To-Book	10.28	7.38	5.17	3.90	3.98

Income Statement (₹ Cr)

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	150.62	1,538.87	2,187.19	2,519.65	3,129.42
Total Income	155.49	1,602.52	2,302.73	2,707.60	3,147.87
Total Expenditure	134.79	1,157.98	1,426.34	1,615.47	2,020.01
EBITDA	15.83	380.89	760.85	904.18	1,109.41
Depreciation	6.07	119.72	72.77	57.73	279.50
EBIT	9.76	261.17	688.08	846.45	829.91
Interest	3.66	58.79	0.87	9.57	192.67
Other Income	4.87	63.65	115.54	187.95	18.45
Exceptional Items	-2.15	12.16	--	-49.16	-17.24
Profit before Tax	10.97	295.31	802.79	975.67	638.54
Provision for Tax	-0.13	51.98	153.06	253.24	-8.97
Profit after Tax	11.10	243.33	649.73	722.43	647.51

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	96.15	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	--	1.04	44.38	--	-7.01
Non-Current Liabilities	22.19	249.46	20.75	19.19	1,149.84
Current Liabilities	57.19	848.06	385.96	627.48	2,201.22
Total Liabilities	175.53	3,705.61	4,037.51	4,921.88	7,246.72

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	85.88	2,578.95	1,451.85	1,046.35	5,582.75
Current Assets	89.65	1,109.77	2,585.66	3,803.22	1,663.97
Total Assets	175.53	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	37.43	657.97	0.57	2.50	2,309.68
Net Current Assets	32.46	261.71	2,199.70	3,175.74	-537.25
Contingent Liabilities	20.24	160.01	17.53	370.49	51.57

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	15.37	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-22.40	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	5.62	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	-1.41	29.88	-105.52	-392.41	-145.00

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	11.87	11.43	24.97	23.39	14.47
ROE (%)	12.27	9.82	20.79	17.16	19.23
ROA (%)	6.76	6.97	17.94	14.91	9.18
EBIT Margin (%)	13.75	28.89	40.07	43.34	36.04
Net Margin (%)	7.14	15.18	28.22	26.68	20.57
Cash Profit Margin (%)	11.40	23.59	33.03	29.72	28.49

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	3.26	19.62	12.89	10.45	8.15
EBIT Growth (%)	48.74	29.72	17.90	19.68	8.91
Net Profit Growth (%)	167.30	210.81	20.08	-5.88	72.82
EPS Growth (%)	167.31	210.80	19.57	-5.88	73.16
Book Value Growth (%)	13.38	9.67	26.75	-0.34	36.71

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	24.08	28.03	17.84	29.89	29.02
Price / Book Value	2.78	2.63	3.27	5.14	4.62
Dividend Yield (%)	0.00	0.17	0.53	1.59	0.00
EV/EBITDA	14.62	16.72	12.43	16.93	17.93
Market Cap (₹ Cr)	267.32	6,819.66	11,439.22	21,592.90	17,980.08

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.39	0.25	0.00	0.00	0.59
Short term debt to equity ratio	0.12	0.16	0.00	0.00	0.12
Current Ratio	1.57	1.31	6.70	6.06	0.76
Quick Ratio	1.06	0.88	5.59	5.31	0.56
Interest Coverage	4.00	6.02	923.75	102.95	4.31

	Bafna Pharma	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	29.17	33.72	37.76	7.22	21.74
Asset Turnover	0.92	0.44	0.60	0.54	0.46
Receivable days	101.91	113.81	121.68	26.06	63.88
Inventory Days	69.05	84.76	63.83	65.95	43.27
Payable days	138.54	101.94	108.28	81.01	151.85
Cash Conversion Cycle	32.41	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.